JP7201400B2 - Ezh2阻害剤組合せ療法 - Google Patents
Ezh2阻害剤組合せ療法 Download PDFInfo
- Publication number
- JP7201400B2 JP7201400B2 JP2018211118A JP2018211118A JP7201400B2 JP 7201400 B2 JP7201400 B2 JP 7201400B2 JP 2018211118 A JP2018211118 A JP 2018211118A JP 2018211118 A JP2018211118 A JP 2018211118A JP 7201400 B2 JP7201400 B2 JP 7201400B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- cancer
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title description 111
- 238000002648 combination therapy Methods 0.000 title description 41
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 205
- 150000003839 salts Chemical class 0.000 claims description 142
- 201000011510 cancer Diseases 0.000 claims description 139
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 114
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 113
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 106
- 239000002246 antineoplastic agent Substances 0.000 claims description 80
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 74
- 229960004316 cisplatin Drugs 0.000 claims description 74
- 229910052697 platinum Inorganic materials 0.000 claims description 53
- 229940034982 antineoplastic agent Drugs 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 28
- 229960005420 etoposide Drugs 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 25
- 239000002552 dosage form Substances 0.000 claims description 17
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 claims description 12
- -1 4-methoxy-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl Chemical group 0.000 claims description 10
- RXCVUHMIWHRLDF-UHFFFAOYSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)C(C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 174
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 120
- 229940125904 compound 1 Drugs 0.000 description 112
- 239000003814 drug Substances 0.000 description 72
- 238000011282 treatment Methods 0.000 description 70
- 150000001875 compounds Chemical class 0.000 description 49
- 239000000203 mixture Substances 0.000 description 47
- 238000000034 method Methods 0.000 description 42
- 229940124597 therapeutic agent Drugs 0.000 description 37
- 238000009472 formulation Methods 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 26
- 229940127089 cytotoxic agent Drugs 0.000 description 25
- 229940079593 drug Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000002195 synergetic effect Effects 0.000 description 19
- 239000003826 tablet Substances 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000003937 drug carrier Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000009097 single-agent therapy Methods 0.000 description 14
- 208000034332 Body integrity dysphoria Diseases 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 241000282320 Panthera leo Species 0.000 description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 108010033040 Histones Proteins 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- 201000000582 Retinoblastoma Diseases 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 10
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 229960004562 carboplatin Drugs 0.000 description 10
- 238000003927 comet assay Methods 0.000 description 10
- 231100000170 comet assay Toxicity 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 230000005778 DNA damage Effects 0.000 description 9
- 231100000277 DNA damage Toxicity 0.000 description 9
- 101000864269 Homo sapiens Schlafen family member 11 Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 102100029918 Schlafen family member 11 Human genes 0.000 description 9
- 230000001028 anti-proliverative effect Effects 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 201000003444 follicular lymphoma Diseases 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 6
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- RXCVUHMIWHRLDF-FQEVSTJZSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(S)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-FQEVSTJZSA-N 0.000 description 5
- PDKDOPJQPKXNCT-UHFFFAOYSA-N 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound CC1=NOC(C)=C1C1=CC(Cl)=C(CCN(CC=2C(NC(C)=CC=2C)=O)C2=O)C2=C1Cl PDKDOPJQPKXNCT-UHFFFAOYSA-N 0.000 description 5
- GIDGCOVAJNOCKD-UHFFFAOYSA-N 5-bromo-8-chloro-2-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-7-(3,5-dimethyltriazol-4-yl)-3,4-dihydroisoquinolin-1-one Chemical compound N1=NN(C)C(C=2C(=C3C(=O)N(CC=4C(NC(C)=CC=4C)=O)CCC3=C(Br)C=2)Cl)=C1C GIDGCOVAJNOCKD-UHFFFAOYSA-N 0.000 description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000006 cell growth inhibition assay Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 229950009791 durvalumab Drugs 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- HRDQQHUKUIKFHT-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindole-4-carboxamide Chemical compound C1=C2N(C(C)C)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCN(C)CC1 HRDQQHUKUIKFHT-UHFFFAOYSA-N 0.000 description 4
- HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000011885 synergistic combination Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- ULNXAWLQFZMIHX-UHFFFAOYSA-N GSK343 Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=C(N=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC ULNXAWLQFZMIHX-UHFFFAOYSA-N 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101100075831 Caenorhabditis elegans mab-7 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 241000581444 Clinidae Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 206010018404 Glucagonoma Diseases 0.000 description 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229950007213 spartalizumab Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LHGUZCKPFXXVPV-GOSISDBHSA-N 1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide Chemical compound C1CN(S(=O)(=O)CC)CCC1[C@@H](C)N1C2=CC=CC=C2C(C(=O)NCC=2C(NC(C)=CC=2OC)=O)=C1C LHGUZCKPFXXVPV-GOSISDBHSA-N 0.000 description 1
- RQOXQFWLPWTPPB-QGZVFWFLSA-N 1-[(1r)-1-[1-(2,2-difluoroethyl)piperidin-4-yl]ethyl]-n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methylindole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)F)CC3)C=2C)=C1OC RQOXQFWLPWTPPB-QGZVFWFLSA-N 0.000 description 1
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- XMEUHPWGPJFKLD-UHFFFAOYSA-N 3-[cyclopentyl(methyl)amino]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(C)C1CCCC1 XMEUHPWGPJFKLD-UHFFFAOYSA-N 0.000 description 1
- XLRMULHWFRKNQV-UHFFFAOYSA-N 3-chloro-4-(2-cyano-3-pyridazin-4-ylphenoxy)-n-(2,2,6,6-tetramethylpiperidin-4-yl)benzamide Chemical compound C1C(C)(C)NC(C)(C)CC1NC(=O)C(C=C1Cl)=CC=C1OC1=CC=CC(C=2C=NN=CC=2)=C1C#N XLRMULHWFRKNQV-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- CPIBUHTWZWSBTE-UHFFFAOYSA-N 5-(6-aminopyridin-3-yl)-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-(2-methylpyrazol-3-yl)benzamide Chemical compound NC1=CC=C(C=N1)C=1C=C(C(=C(C(=O)NCC=2C(NC(=CC2C)C)=O)C1)C)C1=CC=NN1C CPIBUHTWZWSBTE-UHFFFAOYSA-N 0.000 description 1
- LMABPVOSHFLTJO-UHFFFAOYSA-N 5-[2-(dimethylamino)pyrimidin-5-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-(2-methylpyrazol-3-yl)benzamide Chemical compound CN(C1=NC=C(C=N1)C=1C=C(C(=C(C(=O)NCC=2C(NC(=CC2C)C)=O)C1)C)C1=CC=NN1C)C LMABPVOSHFLTJO-UHFFFAOYSA-N 0.000 description 1
- FGZCXBRWZHJWBZ-UHFFFAOYSA-N 5-bromo-3-[cyclopentyl(methyl)amino]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methylbenzamide Chemical compound C=1C(Br)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(C)C1CCCC1 FGZCXBRWZHJWBZ-UHFFFAOYSA-N 0.000 description 1
- JNTZMURDCWYVPI-UHFFFAOYSA-N 5-bromo-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-3-[methyl(oxan-4-yl)amino]benzamide Chemical compound C=1C(Br)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(C)C1CCOCC1 JNTZMURDCWYVPI-UHFFFAOYSA-N 0.000 description 1
- WTLMWQKFNDPIPC-UHFFFAOYSA-N 5-chloro-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methylbenzamide Chemical compound C=1C(Cl)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 WTLMWQKFNDPIPC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- XQFINGFCBFHOPE-WXUXXXNLSA-N C=1C(C#CCN2CCOCC2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)[C@H]1CC[C@H](N(C)CCOC)CC1 Chemical compound C=1C(C#CCN2CCOCC2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)[C@H]1CC[C@H](N(C)CCOC)CC1 XQFINGFCBFHOPE-WXUXXXNLSA-N 0.000 description 1
- LZTJUTULUYEWSE-UHFFFAOYSA-N COCC(C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12 Chemical compound COCC(C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12 LZTJUTULUYEWSE-UHFFFAOYSA-N 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 206010062805 Dysplastic naevus Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- YLVLUDZBBMAFNI-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-5-[2-(methylamino)pyrimidin-5-yl]-3-(2-methylpyrazol-3-yl)benzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=NC1)NC)C1=CC=NN1C)C)=O YLVLUDZBBMAFNI-UHFFFAOYSA-N 0.000 description 1
- BAGJYANQZXICQW-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-5-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-3-(2-methylpyrazol-3-yl)benzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=CC1)N1CCN(CC1)C)C1=CC=NN1C)C)=O BAGJYANQZXICQW-UHFFFAOYSA-N 0.000 description 1
- VUNABXRMGVXNIV-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-(2,4-dimethylpyrazol-3-yl)-2-methyl-5-(2-morpholin-4-ylpyrimidin-5-yl)benzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=NC1)N1CCOCC1)C1=C(C=NN1C)C)C)=O VUNABXRMGVXNIV-UHFFFAOYSA-N 0.000 description 1
- ZRSLJRSRWNXHCQ-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-(2,4-dimethylpyrazol-3-yl)-2-methyl-5-[2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyrimidin-5-yl]benzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=NC1)N1C2COCC1CC2)C2=C(C=NN2C)C)C)=O ZRSLJRSRWNXHCQ-UHFFFAOYSA-N 0.000 description 1
- KLBUHKIAUSWYNS-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-(2,4-dimethylpyrazol-3-yl)-2-methyl-5-[2-(methylamino)pyrimidin-5-yl]benzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=NC1)NC)C1=C(C=NN1C)C)C)=O KLBUHKIAUSWYNS-UHFFFAOYSA-N 0.000 description 1
- BAEWNOYSMKDKJE-GOTSBHOMSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-(2,4-dimethylpyrazol-3-yl)-2-methyl-5-[2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-5-yl]benzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=NC1)N1[C@@H]2CO[C@H](C1)C2)C2=C(C=NN2C)C)C)=O BAEWNOYSMKDKJE-GOTSBHOMSA-N 0.000 description 1
- RGZWOLWVDDAMHM-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-(2,4-dimethylpyrazol-3-yl)-5-[2-(3-fluoroazetidin-1-yl)pyrimidin-5-yl]-2-methylbenzamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(C1=C(C(=CC(=C1)C=1C=NC(=NC1)N1CC(C1)F)C1=C(C=NN1C)C)C)=O RGZWOLWVDDAMHM-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000012247 Oligodendroglial tumor Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000003121 in-cell western assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- WCKDYPHUXUBMEB-UHFFFAOYSA-N n-[(6-methyl-2-oxo-4-propyl-1h-pyridin-3-yl)methyl]-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindazole-4-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=NC(=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC WCKDYPHUXUBMEB-UHFFFAOYSA-N 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 210000003065 pyriform sinus Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229950004774 tazemetostat Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037220 weight regain Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(S)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5-ブロモ-8-クロロ-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-7-(1,4-ジメチル-1H-1,2,3-トリアゾール-5-イル)-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-7-(3,5-ジメチル-1,2-オキサゾール-4-イル)-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-5-[エチル(テトラヒドロ-2H-ピラン-4-イル)アミノ]-4-メチル-4’-(モルホリン-4-イルメチル)ビフェニル-3-カルボキサミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-5-[エチル(テトラヒドロ-2H-ピラン-4-イル)アミノ]-4-メチル-4’-(モルホリン-4-イルメチル)ビフェニル-3-カルボキサミド;
N-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-2-メチル-1-[(1R)-1-[1-(2,2,2-トリフルオロエチル)ピペリジン-4-イル]エチル]-1H-インドール-3-カルボキサミド;
N-(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イルメチル)-1-イソプロピル-3-メチル-6-[6-(4-メチルピペラジン-1-イル)ピリジン-3-イル]-1H-インドール-4-カルボキサミド;
N-[(6-メチル-2-オキソ-4-プロピル-1,2-ジヒドロピリジン-3-イル)メチル]-6-[2-(4-メチルピペラジン-1-イル)ピリジン-4-イル]-1-(プロパン-2-イル)-1H-インダゾール-4-カルボキサミド;
またはこれらの薬学的に許容できる塩からなる群から選択される。
本発明の諸実施形態は、EZH2阻害剤または薬学的に許容できるその塩を含む。
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(S)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
またはこれらの薬学的に許容できる塩からなる群から選択されるEZH2阻害剤が挙げられる。
5-ブロモ-8-クロロ-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-7-(1,4-ジメチル-1H-1,2,3-トリアゾール-5-イル)-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-7-(3,5-ジメチル-1,2-オキサゾール-4-イル)-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
またはこれらの薬学的に許容できる塩からなる群から選択されるEZH2モジュレーターが挙げられる。
5-[2-(ジメチルアミノ)ピリミジン-5-イル]-N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-2-メチル-3-(1-メチル-1H-ピラゾール-5-イル)ベンズアミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-2-メチル-5-[2-(メチルアミノ)ピリミジン-5-イル]-3-(1-メチル-1H-ピラゾール-5-イル)ベンズアミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3-(1,4-ジメチル-1H-ピラゾール-5-イル)-2-メチル-5-[2-(メチルアミノ)ピリミジン-5-イル]ベンズアミド;
5-(6-アミノピリジン-3-イル)-N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-2-メチル-3-(1-メチル-1H-ピラゾール-5-イル)ベンズアミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3-(1,4-ジメチル-1H-ピラゾール-5-イル)-2-メチル-5-(2-モルホリン-4-イルピリミジン-5-イル)ベンズアミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3-(1,4-ジメチル-1H-ピラゾール-5-イル)-2-メチル-5-{2-[(1S,4S)-2-オキサ-5-アザビシクロ[2.2.1]ヘプタ-5-イル]ピリミジン-5-イル}ベンズアミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3-(1,4-ジメチル-1H-ピラゾール-5-イル)-2-メチル-5-{2-[3-オキサ-8-アザビシクロ[3.2.1]オクタ-8-イル]ピリミジン-5-イル}ベンズアミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3-(1,4-ジメチル-1H-ピラゾール-5-イル)-5-[2-(3-フルオロアゼチジン-1-イル)ピリミジン-5-イル]-2-メチルベンズアミド;および
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-2-メチル-5-[6-(4-メチルピペラジン-1-イル)ピリジン-3-イル]-3-(1-メチル-1H-ピラゾール-5-イル)ベンズアミド;
またはこれらの薬学的に許容できる塩からなる群から選択されるEZH2阻害剤が挙げられる。
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-5-[エチル(テトラヒドロ-2H-ピラン-4-イル)アミノ]-4-メチル-4’-(モルホリン-4-イルメチル)ビフェニル-3-カルボキサミド
または薬学的に許容できるその塩が挙げられる。
または薬学的に許容できるその塩であり、これは、2015年12月23日にWO2015/193765として公開された国際特許出願PCT/IB2015/054272で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2015年12月23日にWO2015/193765として公開された国際特許出願PCT/IB2015/054272で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2015年12月23日にWO2015/193765として公開された国際特許出願PCT/IB2015/054272で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2014年6月26日にWO2014/097041として公開された国際特許出願PCT/IB2013/060682で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2014年6月26日にWO2014/097041として公開された国際特許出願PCT/IB2013/060682で開示されており、この文献の内容を参照により本明細書に援用する。
タゼメトスタット(tazemetostat)、EPZ-5687、またはEPZ-6438としても知られる
または薬学的に許容できるその塩であり、これは、2012年10月18日にWO2012/142504として公開された国際特許出願PCT/US2012/033648で開示されており、この文献の内容を参照により本明細書に援用する。
CPI-1205としても知られる
または薬学的に許容できるその塩であり、これは、2013年8月15日にWO2013/120104として公開された国際特許出願PCT/US2013/025639で開示されており、この文献の内容を参照により本明細書に援用する。
GSK-503としても知られる
または薬学的に許容できるその塩であり、これは、2011年11月10日にWO2011/140324として公開された国際特許出願PCT/US2011/035336で開示されており、この文献の内容を参照により本明細書に援用する。
GSK-126としても知られる
または薬学的に許容できるその塩であり、これは、2011年11月10日にWO2011/140325として公開された国際特許出願PCT/US2011/035340で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2011年11月10日にWO2011/140325として公開された国際特許出願PCT/US2011/035340で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2012年5月24日にWO2012/068589として公開された国際特許出願PCT/US2011/061740で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2012年10月18日にWO2012/142513として公開された国際特許出願PCT/US2012/033662で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2013年8月15日にWO2013/120104として公開された国際特許出願PCT/US2013/025639で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2013年8月15日にWO2013/120104として公開された国際特許出願PCT/US2013/025639で開示されており、この文献の内容を参照により本明細書に援用する。
または、場合により酒石酸塩としての、薬学的に許容できるその塩であり、この化合物は、2014年4月24日にWO2014/062720として公開された国際特許出願PCT/US2013/065112で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2014年8月14日にWO2014/124418として公開された国際特許出願PCT/US2014/015706で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2012年10月18日にWO2012/142504として公開された国際特許出願PCT/US2012/033648で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2012年10月18日にWO2012/142513として公開された国際特許出願PCT/US2012/033662で開示されており、この文献の内容を参照により本明細書に援用する。
または薬学的に許容できるその塩であり、これは、2012年10月18日にWO2012/142513として公開された国際特許出願PCT/US2012/033662で開示されており、この文献の内容を参照により本明細書に援用する。
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(S)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5-ブロモ-8-クロロ-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-7-(1,4-ジメチル-1H-1,2,3-トリアゾール-5-イル)-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-7-(3,5-ジメチル-1,2-オキサゾール-4-イル)-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-5-[エチル(テトラヒドロ-2H-ピラン-4-イル)アミノ]-4-メチル-4’-(モルホリン-4-イルメチル)ビフェニル-3-カルボキサミド;
N-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-5-[エチル(テトラヒドロ-2H-ピラン-4-イル)アミノ]-4-メチル-4’-(モルホリン-4-イルメチル)ビフェニル-3-カルボキサミド;
N-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-2-メチル-1-[(1R)-1-[1-(2,2,2-トリフルオロエチル)ピペリジン-4-イル]エチル]-1H-インドール-3-カルボキサミド;
N-(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イルメチル)-1-イソプロピル-3-メチル-6-[6-(4-メチルピペラジン-1-イル)ピリジン-3-イル]-1H-インドール-4-カルボキサミド;
N-[(6-メチル-2-オキソ-4-プロピル-1,2-ジヒドロピリジン-3-イル)メチル]-6-[2-(4-メチルピペラジン-1-イル)ピリジン-4-イル]-1-(プロパン-2-イル)-1H-インダゾール-4-カルボキサミド;
またはこれらの薬学的に許容できる塩からなる群から選択される。
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;
5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(S)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オン;および
5-ブロモ-8-クロロ-2-[(4,6-ジメチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]-7-(1,4-ジメチル-1H-1,2,3-トリアゾール-5-イル)-3,4-ジヒドロイソキノリン-1(2H)-オン;
またはこれらの薬学的に許容できる塩からなる群から選択される。
本発明の諸実施形態は、化学療法剤または薬学的に許容できるその塩に関する。
本発明の方法および組合せ療法は、がん処置に有用である。一部の実施形態では、提供される方法によって、次の効果、すなわち、(1)がん細胞増殖の阻害、(2)がん細胞浸潤性の抑制、(3)がん細胞のアポトーシスの誘発、(4)がん細胞転移の阻害、(5)血管新生の阻害、または(6)がん処置に関連した1つまたは複数の抵抗性機序の克服の1つまたは複数が実現される。
循環器系、たとえば、心臓(肉腫[血管肉腫、線維肉腫、横紋筋肉腫、脂肪肉腫]、粘液腫、横紋筋腫、線維腫、脂肪腫、および奇形腫)、縦隔および胸膜、および他の胸腔内臓器、血管の腫瘍、および腫瘍と関連する血管組織、
呼吸路、たとえば、鼻腔および中耳、副鼻腔、喉頭、気管、気管支、および肺、たとえば、小細胞肺がん(SCLC)、非小細胞肺がん(NSCLC)、気管支原性癌(扁平細胞、未分化小細胞、未分化大細胞、腺癌)、肺胞(気管支)癌、気管支の腺腫、肉腫、リンパ腫、軟骨腫様過誤腫、中皮腫、
胃腸系、たとえば、食道(扁平上皮癌、腺癌、平滑筋肉腫、リンパ腫)、胃(癌腫、リンパ腫、平滑筋肉腫)、胃部、膵臓(腺管腺癌、インスリノーマ、グルカゴノーマ、ガストリノーマ、カルチノイド腫瘍、ビポーマ)、小腸(腺癌、リンパ腫、カルチノイド腫瘍、カポジ肉腫、平滑筋腫、血管腫、脂肪腫、神経線維腫、線維腫)、大腸(腺癌、管状腺腫、絨毛腺腫、過誤腫、平滑筋腫)、
泌尿生殖路、たとえば、腎臓(腺癌、ウィルムス腫瘍[腎芽細胞腫]、リンパ腫、白血病)、膀胱および/または尿道(扁平上皮癌、移行上皮癌、腺癌)、前立腺(腺癌、肉腫)、精巣(精上皮腫、奇形腫、胎児性癌、奇形癌、絨毛癌、肉腫、間質細胞癌、線維腫、線維腺腫、腺腫様腫瘍、脂肪腫)、
肝臓、たとえば、ヘパトーマ(肝細胞癌)、胆管癌、肝芽腫、血管肉腫、肝細胞腺腫、血管腫、膵内分泌腫瘍(たとえば、クロム親和性細胞腫、インスリノーマ、血管作用性小腸ペプチド腫瘍、島細胞腫瘍、およびグルカゴノーマ)、
骨、たとえば、骨原性肉腫(骨肉腫)、線維肉腫、悪性線維性組織球腫、軟骨肉腫、ユーイング肉腫、悪性リンパ腫(細網細胞肉腫)、多発性骨髄腫、悪性巨細胞腫瘍 脊索腫、オステオクロンフローマ(osteochronfroma)(骨軟骨性外骨症)、良性軟骨腫、軟骨芽細胞腫、軟骨粘液線維腫、類骨腫、および巨細胞腫瘍、
神経系、たとえば、中枢神経系(CNS)の新生物、原発性CNSリンパ腫、頭蓋がん(骨腫、血管腫、肉芽腫、黄色腫、変形性骨炎)、髄膜(髄膜腫、髄膜肉腫、神経膠腫症)、脳腫瘍(星状細胞腫、髄芽細胞腫、神経膠腫、上衣腫、胚細胞腫[松果体腫]、多形性神経膠芽腫、乏突起神経膠腫、シュワン腫、網膜芽細胞腫、先天性腫瘍)、脊髄神経線維腫、髄膜腫、神経膠腫、肉腫)、
生殖系、たとえば、婦人科、子宮(子宮内膜癌)、頚部(子宮頚癌、前腫瘍子宮頚部異形成)、卵巣(卵巣癌[漿液性嚢胞腺癌、粘液性嚢胞腺癌、未分類の癌]、顆粒莢膜細胞腫(granulosa-thecal cell tumor)、セルトリ-ライディッヒ細胞腫、未分化胚細胞腫、悪性奇形腫)、外陰(扁平上皮癌、上皮内癌、腺癌、線維肉腫、黒色腫)、膣(明細胞癌、扁平上皮癌、ブドウ状肉腫(胎児性横紋筋肉腫)、卵管(癌腫)、および女性生殖器と関連する他の部位、胎盤、陰茎、前立腺、精巣、および男性生殖器と関連する他の部位、
血液系、たとえば、血液(骨髄性白血病[急性および慢性]、急性リンパ芽球性白血病、慢性リンパ球性白血病、骨髄増殖性疾患、多発性骨髄腫、骨髄異形成症候群)、ホジキン病、非ホジキンリンパ腫[悪性リンパ腫]、
口腔、たとえば、唇、舌、歯肉、口腔底、口蓋、および他の口腔部分、耳下腺および他の唾液腺部分、扁桃、中咽頭、鼻咽頭、梨状陥凹、下咽頭、ならびに唇、口腔、および咽頭における他の部位、
皮膚、たとえば、悪性黒色腫、皮膚黒色腫、基底細胞癌、扁平上皮癌、カポジ肉腫、異形成母斑、脂肪腫、アンジオーマ、皮膚線維腫、およびケロイド、
副腎:神経芽細胞腫、ならびに
結合および軟部組織、後腹膜および腹膜、眼、眼内黒色腫、および付属器を含めた他の組織、乳房、頭または/および頚部、肛門部、甲状腺、副甲状腺、副腎、および他の内分泌腺および関連構造、リンパ節の続発性および未分類の悪性新生物、呼吸器および消化器系の続発性悪性新生物、および他の部位の続発性悪性新生物
のがんを始めとするがん処置に有用となりうる。
本発明の方法および組合せ療法の各治療剤は、単独で、または治療剤と1種もしくは複数の薬学的に許容できる担体、賦形剤、もしくは希釈剤を薬務に従って含む、(本明細書では医薬組成物とも呼ぶ)医薬として投与される場合がある。
「医薬組成物」とは、活性成分としての1種または複数の本明細書に記載の治療剤または薬学的に許容できるその塩、溶媒和物、水和物、もしくはプロドラッグと、少なくとも1種の薬学的に許容できる担体または賦形剤の混合物を指す。一部の実施形態では、医薬組成物は、2種以上の薬学的に許容できる担体および/または賦形剤を含む。
本発明の組合せ療法の治療剤は、血流中、筋肉、または内臓に直接投与してもよい。非経口投与に適する手段には、静脈内、動脈内、腹腔内、くも膜下腔内、脳室内、尿道内、胸骨内、頭蓋内、筋肉内、および皮下が含まれる。非経口投与に適する装置には、(微細針を含めた)有針注射器、無針注射器、および注入技術が含まれる。
本発明の組合せ療法の治療剤は、組成物の共投与に適するキットの形で好都合に組み合わせることができる。
別の態様では、本発明の方法および組合せ療法は、抗腫瘍剤、抗血管新生剤、シグナル伝達阻害剤、抗増殖剤などの、さらなる抗がん剤を、前記がんの処置において合計して有効となる量で投与することをさらに含む場合がある。一部のそうした実施形態では、抗腫瘍剤は、有糸分裂阻害剤、アルキル化剤、代謝拮抗剤、挿入用抗生物質(intercalating antibiotic)、成長因子阻害剤、放射線、細胞周期阻害剤、酵素、トポイソメラーゼ阻害剤、生体応答修飾物質、抗体、細胞傷害性物質、抗ホルモン、アンドロゲン除去療法、および抗アンドロゲン物質からなる群から選択される。一部の実施形態では、抗腫瘍剤は、抗体、たとえば、抗PD-1抗体[たとえば、MDX-1106(ニボルマブ)、MK-3475(ペンブロリズマブ)、CT-011(ピディリズマブ)、REGN2810(セミプリマブ(cemiplimab))、BGB-A317(チスレリズマブ(tislelizumab)またはBGB-A317)、mAb7(RN888またはPF-06801591)、mAb15、AMP-224(B7-DCIg)、AGEN-2034w(AGEN-2034としても知られる)、スパルタリズマブ(spartalizumab)]、抗PD-L1抗体[たとえば、YW243.55.S70、MDX-1105(BMS-936559)、MPDL3280A(アテゾリズマブ)、MEDI4736(デュルバルマブ)、MSB0010718C(アベルマブ)]、および抗CTLA-4抗体[たとえば、イピリムマブ、トレメリムマブ、AGEN-1884]から選択される。
ANCOVA- 共分散分析
BID- 1日2回
BW- 体重
BWL- 体重減少
CR- 完全寛解
DMSO- ジメチルスルホキシド
IP- 腹腔内
Nまたはn- 対象の数
NOD/SCID- 非肥満性糖尿病/重症複合免疫不全症
NS- 重要でない
NSG- NOD scidガンマ
PCR- ポリメラーゼ連鎖反応
PO- 経口
QD- 1日1回
qRT- 定量的実時間
RT- 逆転写
SD- 標準偏差
SEM- 平均値の標準誤差
TGI- 腫瘍成長阻害
WT- 野生型
細胞培養: SCLC細胞株DMS114は、アメリカ培養細胞系統保存機関から入手し(American Type Culture Collection、ATCC CRL-2066)、10%ウシ胎児血清(FBS)(Gibco/Life Technologies Cat.10082-147)および1%ペニシリン/ストレプトマイシンを加えたWaymouth’s Medium MB752/1(Gibco/Life Technologies Cat.11220-035)で培養した。COR-L88(92031917)細胞は、ECACCから購入した。H841(CRL-5845)、H446(HTB-171)、NCI-H889(CRL-5817)、DMS79(CRL2049)、およびH69(HTB-119)は、アメリカ培養細胞系統保存機関から購入し、推奨される培地(H841:5%FBSで補充したHITES培地、H446:COR-L88、NCI-H889:DMS79、およびH69:RPMI-1640培地+10%FBS)で培養した。RPMI1640は、Invitrogen(カタログ番号11875-093、ロット番号1694256)から購入した。HITES培地は、次の成分:0.005mg/mlのインスリンおよび0.01mg/mlのトランスフェリン、30nMの亜セレン酸ナトリウム(ITS-X(Invitrogen、カタログ番号51500-056、ロット番号1582940)、10nMのヒドロコルチゾン(Sigma、カタログ番号H0888-1G、ロット番号061M1142V)、10nMのベータ-エストラジオール(Sigma、カタログ番号E2257-1mg、ロット番号107K8630)、最終濃度を4.5mMとするための追加の2mMのL-グルタミン(Invitrogen、カタログ番号25030-081、ロット番号1552995)、5%ウシ胎児血清(Invitrogen、カタログ番号10099-141、ロット番号1565565)の混合物で補充したDMEM:F12培地(Invitrogen、カタログ番号11320-033、ロット番号1677218)を基本培地として、アメリカ培養細胞系統保存機関の指示に従って調製した。細胞はすべて、加湿したインキュベーターにおいて、37℃、5%二酸化炭素(CO2)で保守した。
(i)化合物製剤:化合物1を、経口経管栄養投与用に、湿式粉砕ナノ懸濁液(2.5%w/vのポリビニルピロリドン(PVP)、0.5%w/vのマクロゴール15ヒドロキシステアレート(Kolliphor HS15)水溶液中で24時間の粉砕、1μm未満の粒度分布(PSD、約650nmの中位径(d50))として製剤化した。
(i)ヒストン抽出:EpiQuickヒストン抽出キット(Epigentek OP0006)を使用して、ヒストン抽出を行った。凍結した腫瘍サンプルをカットし、ドライアイス上で冷えた乳鉢および乳棒を使用して均質化した。均質化された混合物を、1.5mLの管の、フッ化フェニルメタンスルホニル(PMSF)を含有する1×プレ溶解緩衝液(200mg/mL)中へと移した。サンプルを静かに混合し、氷上で15分間インキュベートし、4℃で5分間、3,000rpmで遠心沈殿した。組織ペレットを、ヒストン抽出キットからの3体積(組織100mgあたりおよそ200μL)の溶解緩衝液に再懸濁し、氷上で30分間インキュベートし、4℃で5分間、12,000rpmで遠心沈殿した。DTT溶液をバランス緩衝液に1:500の比で加えることにより、バランス-DTT緩衝液を調製した。(酸可溶性タンパク質を含有する)上清を、新たな1.5mL管に移し、各サンプルに、ヒストン抽出キットからの0.3体積のバランス-ジチオトレイトール(DTT)緩衝液を直ちに加えた。腫瘍可溶化液は、Bioruptor Plus(Diagenode #B01020001)を使用して、高い強度で4サイクル(30秒のオンと30秒のオフ)にわたって短く音波処理した。抽出物を等分し、-20℃(短期間)または-80℃(長期間)で保管した。Coomassie Plus(Bradford)アッセイキット(Thermo #23236)を使用して、タンパク質濃度を定量化した。
DMS114 SCLC細胞における化合物1の抗増殖効果
野生型EZH2を含んでいるDMS114 SCLC細胞において、化合物1のEZH2に対する活性を評価した。細胞H3K27Me3レベルの相対量を測定することにより、EZH2阻害活性を明らかにした。DMS114細胞を、示した濃度の化合物1で3日間処理し、上述のインセルウェスタンアッセイを使用して、H3K27Me3レベルを測定した。結果を表2および図1に示す。図1は、5つの独立した生物学的反復実験を代表するものである。3μM~0.1nMの範囲の濃度で3日間処理後、化合物1は、用量依存的なH3K27Me3阻害を示し、平均細胞IC50は、9.48nMであった。
化合物1とSCLC標準治療剤シスプラチンまたはエトポシドの組合せについての抗増殖相乗作用の評価
SCLC DMS114細胞株の増殖の阻害において化合物1で認められた強い効果を考慮して、現行の標準治療化学療法剤と組み合わせた化合物1を調査した。実験は、DMS114 SCLC細胞についての細胞増殖阻害アッセイを上述の方法に従って使用して行っており、結果を図3および4に示す。図3は、単独で投与した、およびシスプラチンと組み合わせて投与した化合物1についてのIC50曲線を示す。図4は、単独で投与した、およびエトポシドと組み合わせて投与した化合物1についてのIC50曲線を示す。これらの実験は、化合物1での事前の処理によって、DMS114細胞におけるシスプラチンまたはエトポシドの両方またはいずれかの抗増殖効果が強力に増したことを示している。図3および4には、Loewe相加性(ADD)モデルを上述のとおりに使用して、組合せデータをさらに分析した結果も示す。この分析では、両方の化合物についてIC50を上回る用量で実現された増殖阻害のレベルが、両方の化合物の効果が相加的であった場合に予測されるであろうレベルより強力であったことが示された。
単剤化合物1は、DMS114 SCLC異種移植モデルにおける腫瘍成長をin vivoで阻害する。
DMS114 SCLC異種移植モデルにおいて、上述のin vivo異種移植研究プロトコールを使用して、化合物1の抗腫瘍有効性をin vivoで試験した。試験アームの規定、投与形態、および投与経路は、表1に要約されている。結果を図5に示す。化合物1は、用量依存的な有効性反応を示し、最大腫瘍成長阻害(TGI)は、300mg/kgを1日2回(BID)で、69%~79%であった。腫瘍細胞移植後20日目に、腫瘍サイズを基準として、マウスを処置群に無作為化した。各群における無作為化時の腫瘍サイズの幾何平均は、約160mm3であった。図5に示す結果から、100mg/kgBIDおよび300mg/kgBIDで投与された化合物1が、両方とも、ビヒクルが投与された対照群に対して、有意な抗腫瘍利益を示したことを認めることができる。用量依存的な有効性が示され、最高の300mg/kgBID用量についてのTGI利益は、30mg/kgBIDおよび100mg/kgBID処置に対して有意であった(55日目、両側t検定)。化合物1単独療法アームでは、完全な腫瘍退縮は、認められなかった。化合物1は、体重減少が限られ、十分に忍容された。
単剤化合物1は、DMS114 SCLC異種移植モデルにおいて、in vivoでH3K27Me3およびMe2の用量依存的なバイオマーカー阻害を示す。
DMS114 SCLC異種移植モデルにおける化合物1のEZH2に対するin vivo活性を、上記実施例3に記載の研究からの、55日目に回収した腫瘍組織サンプルを使用して、ELISAによって、細胞H3K27Me3およびMe2レベルの相対量を測定することにより明らかにした。結果を図6に示す。化合物1は、腫瘍サンプルにおいてH3K27Me3およびMe2の用量依存的な阻害を示し、最大阻害は、H3K27Me3およびMe2について、300mg/kgBIDで、それぞれ、96%および82%であった。
化合物1は、DMS114 SCLC異種移植モデルにおいて、シスプラチンと、組合せによる抗腫瘍活性利益を示す。
EZH2-WT DMS114 SCLC異種移植モデルにおいて、上述のin vivo異種移植研究プロトコールを使用して、シスプラチンと組み合わせた化合物1の抗腫瘍有効性をin vivoで試験した。試験アームの規定、投与形態、および投与経路は、表1に要約されている。結果を図7に示す。55日目に、シスプラチンおよび化合物1単独処置群では、シスプラチン投与後に断続的な腫瘍の縮小が認められたとはいえ、すべての腫瘍が進行し、処置開始時より大きくなっていた。対照的に、組合せ群では、12のうち6の腫瘍が、出発腫瘍負荷に比べて退縮していた。55日目までに、組合せ処置では、TGIが95%となり、シスプラチン(TGIは51%、シスプラチンに対してP=0.019)または化合物1(TGIは50%、100mg/kgの化合物1に対してP=0.016)での単剤療法より有意に効果的であった。シスプラチン処置は、マウスの体重減少を引き起こしたため、単剤および組合せアームの両方において3回目の投与後に中止した(図7)。化合物1単剤処置は、十分に忍容されたが(図7)、化合物1+シスプラチンの組合せは、体重減少を示し、シスプラチン単剤療法処置群より有意に顕著であった(27日目以降のすべての測定についてP<0.05、両側t検定)。
追加のSCLC細胞株における化合物1の抗増殖効果
DMS114細胞において化合物1で認められた強い活性(上記実施例1を参照されたい)に基づき、化合物1の抗増殖活性を、追加の3種のSCLC細胞株、すなわち、H841、H446、およびH69においても、上述の細胞増殖アッセイを使用して試験した。3μM~0.1nMの10段階用量曲線(DMSO中に1:3希釈)を使用して、各細胞株を、異なる濃度の化合物1で21日間処理し、次いで、細胞生存率について評価した。結果を、図10(H841)、図11(H446)、および図12(H69)に示す。21日間の処理後、化合物1は、用量依存的な強い細胞増殖阻害を示し、平均IC50は、H841細胞株で73.15nM、H446細胞株で108.6nM、H69細胞株で224.1nMであった。
H841、H446、およびH69細胞株における、化合物1とSCLC標準治療剤シスプラチンまたはエトポシドの組合せについての抗増殖相乗作用の評価
SCLC H841、H446、およびH69細胞株の増殖の阻害において化合物1で認められた強い効果を考慮して、化合物1の、現行の標準治療化学療法剤シスプラチンまたはエトポシドとの組合せを調査した。実験は、H841、H446、またはH69 SCLC細胞についての細胞増殖阻害アッセイを、上述の方法に従って使用して行っており、結果を、図13および14(H841細胞株)、図15および16(H446細胞株)、ならびに図17および18(H69細胞株)に示す。図13、15、および17は、単独で投与した、およびシスプラチンと組み合わせて投与した化合物1についてのIC50曲線を示す。図14、16、および18は、単独で投与した、およびエトポシドと組み合わせて投与した化合物1についてのIC50曲線を示す。DMS114でのように、これらの実験も、化合物1での事前の処理によって、H841、H446、およびH69細胞株におけるシスプラチンまたはエトポシドの両方またはいずれかの抗増殖効果が強力に増したことを示している。
化合物1は、SCLC細胞株におけるSLFN11の発現を誘導する。
化学療法剤を用いて認められたEZH2i相乗作用を担う潜在的な機序を理解するために、本発明者らは、DNA傷害剤にとっての感作物質であるSLFN11発現に対する、化合物1処理の効果を評価した。いくつかのSCLC細胞株を500nMの化合物1で7日間処理し、ウェスタンブロッティングを上述の方法に従って使用して、SLFN11タンパク質レベルの変化を評価した。結果を図19に示す。こうした結果は、化合物1で処理すると、いくつかの細胞株において、SLFN11発現の強い誘導が認められたことを示している。
化合物1とSCLC標準治療剤シスプラチンの組合せは、SCLC細胞株においてDNA損傷の増加を誘発する。
DNA損傷マーカーであるγ-H2AXの染色またはCOMETアッセイを用いたDNA損傷の評価のいずれかを、上述の方法に従って使用して、化学療法剤シスプラチンと組み合わせた化合物1の、DNA損傷に対する効果を評価した。SCLC細胞株H841またはH69を化合物1で7日間事前処理した後、シスプラチンで16時間(γ-H2AX)または3日間(COMETアッセイ)補助処理した。 結果を図20~22に示す。図20において、H841細胞株からの結果は、組合せで処理した細胞において、いずれかの単剤療法で処理した細胞に比べて、γ-H2AXフォーカス形成の激しい増加が認められたことを示唆している。図21において、H841細胞株からの結果は、組合せで処理した細胞において、いずれかの単剤療法で処理した細胞に比べて、DNA損傷(COMETアッセイ)の激しい増加が認められたことを示唆している。H69細胞株COMETアッセイでも、同様の結果が得られた(図22を参照されたい)。
Claims (7)
- 5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンまたは薬学的に許容できるその塩を含む医薬組成物であって、対象におけるがん(ここで、がんは小細胞肺がんである)処置に白金系抗新生物剤(ここで、白金系抗新生物剤はシスプラチンである)または薬学的に許容できるその塩と組合せて用いるための医薬組成物。
- 小細胞肺がんが、進展期疾患として分類される、請求項1に記載の医薬組成物。
- 5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンが、5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンである、請求項1または2に記載の医薬組成物。
- さらにエトポシドと組み合わせて用いるための、請求項1から3のいずれか一項に記載の医薬組成物。
- 5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンまたは薬学的に許容できるその塩とシスプラチンとを含み、前記5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンまたは薬学的に許容できるその塩と、前記シスプラチンとが、それぞれ別個の投薬単位剤形である、小細胞肺がんの処置に用いるためのキット。
- 前記5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンまたは薬学的に許容できるその塩と、前記シスプラチンとが、順次投与される、請求項5に記載のキット。
- 5,8-ジクロロ-2-[(4-メトキシ-6-メチル-2-オキソ-1,2-ジヒドロ-ピリジン-3-イル)メチル]-7-[(R)-メトキシ(オキセタン-3-イル)メチル]-3,4-ジヒドロイソキノリン-1(2H)-オンまたは薬学的に許容できるその塩と、シスプラチンとを含む、小細胞肺がんの処置に用いるための医薬組成物。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762585781P | 2017-11-14 | 2017-11-14 | |
US62/585781 | 2017-11-14 | ||
US201862628314P | 2018-02-09 | 2018-02-09 | |
US62/628314 | 2018-02-09 | ||
US201862684832P | 2018-06-14 | 2018-06-14 | |
US62/684832 | 2018-06-14 | ||
US201862739990P | 2018-10-02 | 2018-10-02 | |
US62/739990 | 2018-10-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019116465A JP2019116465A (ja) | 2019-07-18 |
JP2019116465A5 JP2019116465A5 (ja) | 2021-11-18 |
JP7201400B2 true JP7201400B2 (ja) | 2023-01-10 |
Family
ID=64453535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018211118A Active JP7201400B2 (ja) | 2017-11-14 | 2018-11-09 | Ezh2阻害剤組合せ療法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US11529344B2 (ja) |
EP (1) | EP3710057A1 (ja) |
JP (1) | JP7201400B2 (ja) |
KR (1) | KR20200088386A (ja) |
CN (1) | CN111356478A (ja) |
AU (1) | AU2018369841A1 (ja) |
BR (1) | BR112020008325A2 (ja) |
CA (1) | CA3082287C (ja) |
IL (1) | IL274415A (ja) |
MX (1) | MX2020004731A (ja) |
RU (1) | RU2754131C1 (ja) |
SG (1) | SG11202003477QA (ja) |
TW (1) | TWI698238B (ja) |
WO (1) | WO2019097369A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017519013A (ja) | 2014-06-17 | 2017-07-13 | ファイザー・インク | 置換ジヒドロイソキノリノン化合物 |
WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2017192290A1 (en) | 2016-05-04 | 2017-11-09 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
DE60033530T2 (de) | 1999-08-24 | 2007-10-31 | Medarex Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
US20110223188A1 (en) | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
BR122021025338B1 (pt) | 2009-11-24 | 2023-03-14 | Medimmune Limited | Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos |
EP2566479B1 (en) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Azaindazoles |
PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
HUE028977T2 (en) | 2010-09-10 | 2017-02-28 | Epizyme Inc | A method for determining the suitability of human EZH2 inhibitors during treatment |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
KR101339500B1 (ko) | 2011-10-18 | 2013-12-09 | 경상대학교산학협력단 | 쌀벌레 방제용 소형 패치 및 젤 |
HUE051954T2 (hu) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | ANTI-PD-L1 ellenanyagok és alkalmazásaik |
AU2013216721B2 (en) | 2012-02-10 | 2017-09-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
NZ746054A (en) | 2012-10-15 | 2020-07-31 | Epizyme Inc | Methods of treating cancer |
EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
CN107011441B (zh) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
CA2926423C (en) | 2013-10-07 | 2022-05-24 | Google Inc. | Automated crowdsourced power outage identification and staggering of hvac system restarts |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
PT3303394T (pt) | 2015-05-29 | 2020-07-01 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
JP6839761B2 (ja) | 2016-12-08 | 2021-03-10 | イーライ リリー アンド カンパニー | 抗PD−L1抗体との組み合わせのための抗Tim−3抗体 |
-
2018
- 2018-11-09 CN CN201880073705.2A patent/CN111356478A/zh active Pending
- 2018-11-09 WO PCT/IB2018/058795 patent/WO2019097369A1/en unknown
- 2018-11-09 KR KR1020207016752A patent/KR20200088386A/ko not_active Application Discontinuation
- 2018-11-09 JP JP2018211118A patent/JP7201400B2/ja active Active
- 2018-11-09 RU RU2020115715A patent/RU2754131C1/ru active
- 2018-11-09 SG SG11202003477QA patent/SG11202003477QA/en unknown
- 2018-11-09 EP EP18807711.9A patent/EP3710057A1/en active Pending
- 2018-11-09 CA CA3082287A patent/CA3082287C/en active Active
- 2018-11-09 MX MX2020004731A patent/MX2020004731A/es unknown
- 2018-11-09 AU AU2018369841A patent/AU2018369841A1/en not_active Abandoned
- 2018-11-09 BR BR112020008325-9A patent/BR112020008325A2/pt not_active Application Discontinuation
- 2018-11-09 TW TW107139825A patent/TWI698238B/zh not_active IP Right Cessation
- 2018-11-09 US US16/762,388 patent/US11529344B2/en active Active
-
2020
- 2020-05-04 IL IL274415A patent/IL274415A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017519013A (ja) | 2014-06-17 | 2017-07-13 | ファイザー・インク | 置換ジヒドロイソキノリノン化合物 |
WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2017192290A1 (en) | 2016-05-04 | 2017-11-09 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs |
Non-Patent Citations (1)
Title |
---|
Cancer Cell,2017年02月,Vol.31,pp.286-299 |
Also Published As
Publication number | Publication date |
---|---|
TWI698238B (zh) | 2020-07-11 |
CA3082287A1 (en) | 2019-05-23 |
JP2019116465A (ja) | 2019-07-18 |
BR112020008325A2 (pt) | 2020-10-20 |
US20200268740A1 (en) | 2020-08-27 |
TW201936182A (zh) | 2019-09-16 |
IL274415A (en) | 2020-06-30 |
CN111356478A (zh) | 2020-06-30 |
KR20200088386A (ko) | 2020-07-22 |
EP3710057A1 (en) | 2020-09-23 |
WO2019097369A1 (en) | 2019-05-23 |
SG11202003477QA (en) | 2020-05-28 |
RU2754131C1 (ru) | 2021-08-27 |
CA3082287C (en) | 2023-02-28 |
MX2020004731A (es) | 2020-10-28 |
AU2018369841A1 (en) | 2020-05-07 |
US11529344B2 (en) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11446309B2 (en) | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors | |
AU2014372166B2 (en) | Pharmaceutical combinations | |
US20230033324A1 (en) | Combination therapy for treatment of cancer | |
US20160287605A1 (en) | Combination therapy | |
CA2725390C (en) | Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer | |
KR20180041677A (ko) | Mdm2 억제제 및 그의 조합물 | |
CA2861056A1 (en) | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
KR20160126984A (ko) | 아필리모드 조성물 및 이를 사용하기 위한 방법 | |
US20160213669A1 (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer | |
US20160303137A1 (en) | Dual pi3k and wnt pathway inhibition as a treatment for cancer | |
JP2020515582A (ja) | 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート | |
US20190000850A1 (en) | Combination cancer therapy | |
KR20220011651A (ko) | Gapdh를 억제하기 위한 방법 및 조성물 | |
JP7201400B2 (ja) | Ezh2阻害剤組合せ療法 | |
AU2010235917A1 (en) | Combination of organic compounds | |
JP2022533100A (ja) | Notch活性化乳がんを治療するためのビスフルオロアルキル-1,4-ベンゾジアゼピノン化合物 | |
JP2018537519A (ja) | 癌の治療のための合理的併用療法 | |
WO2013149026A2 (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl) -2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer | |
JP2022514056A (ja) | 癌の治療に使用するためのRaf阻害剤及びCDK4/6阻害剤による組み合わせ療法 | |
US20130310352A1 (en) | Dexamethasone combination therapy | |
CA2894153A1 (en) | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder | |
US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
JP2023513016A (ja) | Nek2阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体 | |
WO2021050900A1 (en) | Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder | |
TW202332431A (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211007 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211007 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221209 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7201400 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |